FDA Grants Emergency Use Authorization to Alberta Vet Labs' Ivermectin Liquid for Horses to Prevent New World Screwworm
1. FDA's Emergency Use Authorization for New World Screwworm Prevention
The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) on July 15, 2026, for Ivermectin Liquid for Horses from Alberta Vet Labs Ltd. This action is part of a federal public health initiative to proactively address the spread of New World Screwworm (NWS) in the United States. Ivermectin targets glutamate-gated chloride channels (GluCl) in invertebrates, paralyzing the parasites. Although not yet fully approved, it has been recognized as an essential preventative measure to reduce mortality from myiasis in horses.
2. Clinical Significance of Myiasis Prevention and Early Parasite Control
New World Screwworm (NWS) is an external parasite that lays eggs in the wounds of horses or the umbilical area of foals, where the larvae multiply. These larvae feed on the animal's living skin tissue, causing severe myiasis and potentially leading to death. The approval of Alberta Vet Labs' Ivermectin Liquid is significant because it inhibits larval growth and breaks the parasite's life cycle in the early stages of infection. Administered orally immediately after injury or shortly after birth, it provides a rapid and safe preventative protocol.
3. Securing Early Treatment Window for Competitive Advantage
The key to this EUA is administering the drug within 24 hours of birth or immediately after injury to secure the critical treatment window. This is a significant differentiator compared to Dectomax (Doramectin), an injectable approved by Zoetis (ZTS) in May 2026. Zoetis' injectable is only approved for horses over one year old, while Alberta Vet Labs' liquid formulation can be safely used in newborn foals. As a result, Alberta Vet Labs gains a commercial advantage by capturing the market for newborn animals, which are particularly vulnerable to infection.
4. Growth in the Animal Anthelmintic Market and Benefits to Veterinary Public Health
The global animal anthelmintic market was valued at approximately $9.2 billion in 2025 and is growing at an annual rate of over 6%. The North American equine healthcare market, valued at approximately $1.7 billion, also maintains a robust ecosystem, ensuring steady demand for related preventative medicines. The FDA's rapid activation of the EUA process in this crisis sets a precedent for how regulatory agencies can make swift decisions in future outbreaks of similar parasites and infectious diseases. The granting of the EUA to Alberta Vet Labs is considered a groundbreaking case of a private pharmaceutical company entering the veterinary public health market and generating revenue.
With the Emergency Use Authorization (EUA) granted to Alberta Vet Labs (AVL) for its Ivermectin Liquid for Horses, the global equine healthcare market, valued at up to $4.6 billion in 2025, is expected to see significant growth in the pediatric/neonatal preventative medicine segment. In the short term, it is expected to capitalize on the market for newborn foal protection within 24 hours of birth, filling the gap left by the EUA granted to competitor Zoetis' Dectomax in May 2026, which is limited to horses over one year old. In the medium to long term, amid the spread of New World Screwworm (NWS) in North America due to climate change, it will accelerate the establishment of early treatment standards (SoC) for Ivermectin, which targets glutamate-gated chloride channels (GluCl). Furthermore, this case provides a precedent for the rapid public procurement of unapproved drugs in the global animal anthelmintic market, valued at $12 billion annually, and is expected to serve as a regulatory and business benchmark for future responses to emerging zoonotic infectious diseases.